Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 13Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Neoplasm Metastasis 3Stomatitis 2Stomach Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Trauma, Nervous System 1Thromboembolism 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Lipoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Intracranial Hemorrhages 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Saline Solution × Clear all
NCT03515837 2024-11-22

MK-3475-789

Merck Sharp & Dohme LLC

Phase 3 Completed
492 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
616 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
40 enrolled 20 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT00850577 2015-10-12

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Bristol-Myers Squibb

Phase 2 Terminated
255 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡